Brian Goff sold $627k of AGIO
Chief Executive Officer at AGIOS PHARMACEUTICALS, INC.. 18,700 shares at an average of $33.54, traded Jun 24, 2025, filed Jun 26, 2025.
Score components
- +25RoleCEO
- +20Trade size$627k at market
- +5Share of holdings soldSold 16% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001439222-25-000063, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 24, 2025 | MOption exercise Common stock10b5-1 | +25,527 | $0.00 | $0 | 117,872 | Jun 26, 2025 |
| Jun 24, 2025 | SOpen-market sale Common stock10b5-1 | -12,471 | $33.54 | $418k | 105,401 | Jun 26, 2025 |
| Jun 24, 2025 | MOption exercise Common stock10b5-1 | +12,750 | $0.00 | $0 | 118,151 | Jun 26, 2025 |
| Jun 24, 2025 | SOpen-market sale Common stock10b5-1 | -6,229 | $33.54 | $209k | 111,922 | Jun 26, 2025 |
| Jun 24, 2025 | MOption exercise Performance share unitsderivative10b5-1 | -25,527 | $0.00 | $0 | 51,056 | Jun 26, 2025 |
| Jun 24, 2025 | MOption exercise Performance share unitsderivative10b5-1 | -12,750 | $0.00 | $0 | 12,750 | Jun 26, 2025 |
Related signals
Other insiders at AGIOS PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | AGIOS PHARMACEUTICALS, INC. | Cecilia Jones Chief Financial Officer | $134k 3,651 shares | -10% | |
| 57Moderate | AGIOS PHARMACEUTICALS, INC. | Theodore James Washburn Jr. Principal Accounting Officer | $315k 8,546 shares | -91% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | David Scadden director | $8,000 200 shares | -1% | |
| 6Weak | AGIOS PHARMACEUTICALS, INC. | Brian Goff Chief Executive Officer | $406k 11,085 shares | -8% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | David Scadden director | $56k 1,400 shares | -7% | |
| 10Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $453k 11,914 shares | -16% | |
| 6Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $140k 4,091 shares | -6% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | Tsveta Milanova Chief Commercial Officer | $93k 2,770 shares | -10% | |
| 9Weak | AGIOS PHARMACEUTICALS, INC. | Cecilia Jones Chief Financial Officer | $60k 1,780 shares | -6% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $98k 2,909 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.